Primary source: Center for Drug Evaluation and Research 2026 Guidance Agenda
Mandatory updates to purity characterization and immunogenicity assessment protocols for generic peptide products outlined in the 17 revised PSGs, effective from the published date.
These changes reflect an essential evolution in the FDA's approach, potentially leading to increased safety and efficacy of generic peptide medications, which are critical for conditions like diabetes and osteoporosis.
Sponsors and clinical safety teams must revise and enhance their protocols for impurity analysis and immunogenicity assessments in alignment with the newly released guidances, ensuring all future ANDAs meet updated safety criteria.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Inclusion of recommendations for impurity profile analysis in ANDA submissions; requirement for a comparative analysis of impurity and immunogenicity profiles between the generic and reference drug; updates to scientific standards for 17 specific peptide products including Calcitonin salmon and Dasiglucagon.
Sponsors and clinical safety teams developing generic peptides must update their impurity characterization and immunogenicity assessment protocols. The emphasis on immunogenicity risk assessment means that post-marketing safety monitoring strategies may need to be more robust for products with identified impurity differences. Clinical safety departments should review the 17 specific guidances to ensure that ongoing or planned bioequivalence studies meet the updated safety characterization criteria.
Sponsors and clinical safety teams must revise and enhance their protocols for impurity analysis and immunogenicity assessments in alignment with the newly released guidances, ensuring all future ANDAs meet updated safety criteria.
The FDA has published 17 revised draft product-specific guidances (PSGs) for certain generic peptide products, focused on improving assessment methods for generic drug applications (ANDAs). Key updates include enhanced impurity profiling and immunogenicity risk assessment, requiring sponsors to adjust protocols accordingly to ensure compliance with current safety standards.
What changed: Mandatory updates to purity characterization and immunogenicity assessment protocols for generic peptide products outlined in the 17 revised PSGs, effective from the published date.
Why it matters: These changes reflect an essential evolution in the FDA's approach, potentially leading to increased safety and efficacy of generic peptide medications, which are critical for conditions like diabetes and osteoporosis.
Practical implication: Sponsors and clinical safety teams must revise and enhance their protocols for impurity analysis and immunogenicity assessments in alignment with the newly released guidances, ensuring all future ANDAs meet updated safety criteria.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
